UCSF Scientists Reprogram T Cells Inside the Body to Destroy Cancer
A new CRISPR-based two-particle system engineers cancer-fighting CAR-T cells directly inside the body, cutting cost, time, and complexity.
Summary
Researchers at UC San Francisco have developed a method to create CAR-T cancer-fighting immune cells directly inside the body using CRISPR gene editing. Currently, CAR-T therapy requires removing a patient's T cells, sending them to a lab for genetic modification, and reinfusing them weeks later at a cost of up to $500,000. The new approach uses a two-particle delivery system to insert cancer-targeting DNA precisely into T cells without ever taking them out of the body. In mice with humanized immune systems, the technique successfully fought leukemia, multiple myeloma, and a solid tumor. If translated to humans, this could make CAR-T therapy dramatically faster, cheaper, and more widely accessible, including for older or medically frail patients who struggle with current treatment demands.
Detailed Summary
CAR-T cell therapy is one of oncology's most powerful tools, but it remains out of reach for many patients due to its staggering cost and logistical complexity. The standard process requires extracting a patient's T cells, shipping them to a specialized facility, genetically engineering them to recognize cancer, and reinfusing them weeks later — a process costing $400,000 to $500,000 and leaving patients waiting while their disease progresses.
A team at UC San Francisco has now developed an approach that sidesteps this entire manufacturing pipeline. Using a two-particle delivery system, scientists sent CRISPR gene-editing tools and new cancer-targeting DNA directly into T cells still inside the body, inserting the DNA at a precise genomic location. This marks the first time a large stretch of DNA has been site-specifically inserted into human T cells in vivo.
In mouse models with humanized immune systems, the method proved effective against aggressive leukemia, multiple myeloma, and even a solid tumor — a notoriously difficult target for CAR-T therapies. Critically, the targeted insertion strategy outperformed the conventional viral method of inserting DNA at random locations, suggesting broader implications for gene and cell therapy beyond cancer.
The implications for aging and longevity are meaningful. Older and medically frail patients currently struggle with the intensive chemotherapy required before CAR-T infusion. A faster, in-body approach could lower that burden significantly and open treatment to patients who are otherwise excluded. Blood cancers disproportionately affect older adults, making accessibility improvements directly relevant to longevity medicine.
The research, published in Nature, is still at the preclinical stage. Human trials have not yet begun, and translating the delivery system safely and effectively to people remains a substantial challenge. Nevertheless, researchers describe this as the start of a transformational wave in cell and gene therapy.
Key Findings
- CRISPR tools delivered in vivo reprogrammed T cells into CAR-T cancer fighters without removing them from the body.
- The two-particle system achieved precise DNA insertion at a targeted genomic location, outperforming standard viral methods.
- In humanized-immune-system mice, the approach fought leukemia, multiple myeloma, and a solid tumor successfully.
- Eliminating ex vivo manufacturing could reduce CAR-T costs from ~$500,000 and cut weeks off treatment timelines.
- Older and frail patients who cannot tolerate intensive pre-treatment chemotherapy may particularly benefit from this approach.
Methodology
This is a news report summarizing a primary research paper published in Nature by UC San Francisco scientists. Evidence is preclinical, based on mouse models with humanized immune systems. The source institution and journal are highly credible, but human trial data are not yet available.
Study Limitations
All efficacy data come from mouse models with humanized immune systems; human safety and efficacy are unproven. The article is a news summary and does not provide full methodological details — primary Nature paper should be consulted. Long-term durability of in vivo-engineered CAR-T cells and potential off-target CRISPR effects are not addressed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: